10-K: HCA Healthcare's Strong 2025: Revenue Up 7.1%, Net Income Jumps 17.8%

HCA Healthcare reports robust financial performance in 2025 with significant revenue and net income growth, driven by increased patient volumes and strategic investments in digital and AI capabilities.

Summary

• Net income attributable to HCA Healthcare, Inc. was $6.784 billion ($28.33 per diluted share) in 2025, up from $5.760 billion ($22.00 per diluted share) in 2024.
• Revenues increased 7.1% to $75.600 billion in 2025 from $70.603 billion in 2024.
• Consolidated equivalent admissions increased by 2.9%, and revenue per equivalent admission increased by 4.0% in 2025.
• Same facility revenues increased 6.6%, resulting from a 2.4% increase in equivalent admissions and a 4.1% increase in revenue per equivalent admission.
• Cash flows from operating activities rose by $2.122 billion to $12.636 billion in 2025.
• The company repurchased 26.739 million shares of common stock for $10.067 billion in 2025.
• Medicaid state-directed and supplemental payment programs contributed approximately $6.2 billion in 2025, up from $5.5 billion in 2024.
• The estimated cost of total uncompensated care increased by $239 million to $4.605 billion in 2025 compared to 2024.
• HCA operated 190 hospitals, 121 freestanding ambulatory surgery centers (ASCs), and 31 freestanding endoscopy centers as of December 31, 2025.
• The Board of Directors declared a quarterly dividend of $0.78 per share payable on March 31, 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong performance, with significant growth in key financial metrics and strategic advancements in technology and market presence. The positive operational trends and capital allocation to shareholders are notable, despite some anticipated regulatory headwinds and cost pressures.

Positives

• Net income attributable to HCA Healthcare, Inc. increased by 17.8% to $6.784 billion in 2025.
• Strong revenue growth of 7.1% to $75.600 billion in 2025.
• Consolidated equivalent admissions increased by 2.9%, indicating higher patient volume.
• Revenue per equivalent admission increased by 4.0%, suggesting improved pricing or service mix.
• Cash flows from operating activities increased substantially by $2.122 billion to $12.636 billion.
• Successful share repurchase program, with 26.739 million shares repurchased in 2025.
• Increased quarterly dividend to $0.78 per share, signaling confidence in future cash flows.
• Strategic investments in clinical systems, digital capabilities, AI, and workforce development.
• Salaries and benefits as a percentage of revenues decreased from 44.1% in 2024 to 43.5% in 2025, indicating improved labor cost management.
• Decline in supply costs per equivalent admission for pharmacy supplies by 4.0% in 2025.
• Successful resolution of IRS examinations for 2022 and 2023 income tax returns with no material impact.
• Management concluded that internal control over financial reporting was effective as of December 31, 2025.

Negatives

• Outpatient surgical volumes declined by 0.2% on a consolidated basis and 0.5% on a same-facility basis in 2025.
• Estimated cost of total uncompensated care increased by $239 million in 2025, reaching $4.605 billion.
• Interest expense increased by $187 million to $2.248 billion in 2025, primarily due to an increase in the average debt balance.
• Working capital declined from $1.237 billion at December 31, 2024, to negative $567 million at December 31, 2025, primarily due to a decline in cash and an increase in short-term borrowings.
• Revenues from Medicaid state-directed payment (SDP) arrangements are expected to decline in 2026 compared to 2025, excluding the impact of any additional approvals.
• Anticipated adverse impact on results of operations in 2026 due to administrative reforms related to Exchanges and the expiration of enhanced premium tax credits.
• Inflationary pressures are expected to continue impacting operating expenses in 2026.
• Ongoing legal challenges relating to the No Surprises Act's independent dispute resolution (IDR) process create uncertainty and delays in claims resolution.
• Net unrealized losses of $14 million on the insurance subsidiaries' investment securities at December 31, 2025.

Risks

• Significant indebtedness of $46.492 billion at December 31, 2025, could adversely affect the ability to raise additional capital, limit reactions to economic/industry changes, expose to interest rate risk, and prevent meeting obligations.
• Inability to generate sufficient cash to service all indebtedness or refinance on favorable terms.
• Debt agreements contain restrictions that limit flexibility in operating the business.
• Results of operations may be adversely affected by competition for staffing, shortages of experienced nurses and other healthcare professionals, and labor union activity.
• Performance depends on the ability to recruit and retain quality physicians.
• Inability to attract, hire, and retain a highly qualified workforce, including key management.
• Cybersecurity incidents or other forms of data breaches could result in compromise of facilities, confidential data, or critical data systems, causing operational impairment, harm to patients, remediation expenses, and exposure to liability.
• Operations could be impaired by a failure in or breach of information systems or those of third parties.
• Health care technology initiatives, particularly those related to sharing patient data, interoperability, and AI, involve risks that may adversely affect operations.
• Failure to effectively manage change associated with technology, resiliency, and EHR platform implementation may adversely affect business, services, and results of operations.
• The emergence and effects related to a potential future pandemic, epidemic, or outbreak of an infectious disease could adversely affect business and operations.
• Business, financial condition, and results of operations may be adversely affected by changes and uncertainty in the health care industry, including public policy developments and other changes to laws and regulations.
• Changes in government health care programs (Medicare, Medicaid) may adversely affect revenues and business.
• Failure to comply with extensive laws and government regulations could result in penalties or require significant changes to operations.
• State efforts to regulate the construction or expansion of health care facilities could impair the ability to operate and expand operations.
• Potential for additional tax liabilities from changes in tax laws or audits.
• Could become the subject of government investigations, claims, and litigation, as well as governmental and commercial payer audits.
• May be subject to liabilities from claims brought against facilities, which are costly to defend and may require significant damages if not covered by insurance.
• Hospitals and other facilities face competition for patients from other hospitals and health care providers.
• Any increase in the volume of uninsured patients or deterioration in the collectability of uninsured and patient due accounts could adversely affect results of operations.
• If the volume of patients with private health insurance coverage declines or the company is unable to retain and negotiate favorable contracts with private third-party payers, revenues may be adversely affected.
• Changes to physician utilization practices and treatment methodologies and other factors outside control that impact demand for medical services may reduce revenues.
• Third-party payer controls designed to reduce costs and other payer practices intended to decrease inpatient services, surgical procedure volumes, or reimbursement for services rendered may reduce revenues.
• May encounter difficulty acquiring hospitals and other health care businesses, encounter challenges integrating operations, and/or become liable for unknown or contingent liabilities as a result of acquisitions.
• Facilities are heavily concentrated in Florida and Texas (51% of consolidated revenues), making the company sensitive to regulatory, economic, public health, environmental, and competitive conditions in those states.
• Business and operations are subject to risks related to hurricanes, extreme weather events, or other natural disasters.
• The industry trend toward value-based purchasing may negatively impact revenues.
• Overall business results may suffer during periods of significant inflation, general economic weakness or recessions, or as a result of changing governmental policies.
• Exposure to market risk related to changes in the market values of securities and interest rates.
• No assurance that the company will continue to pay dividends.
• Certain investors (Frist-affiliated) may continue to have influence over the company.

Future Outlook

HCA Healthcare anticipates a decline in revenues from Medicaid state-directed payment (SDP) arrangements in 2026, excluding additional approvals. The expiration of enhanced premium tax credits and administrative reforms related to Exchanges are expected to adversely affect 2026 results, though partially offset by ongoing resiliency efforts. Inflationary pressures are projected to continue impacting operating expenses. Planned capital expenditures for 2026 are estimated between $5.0 billion and $5.5 billion, with approximately $7.1 billion allocated for projects under construction over the next five years. The company will continue to adapt to evolving regulatory changes, including the phase-out of the Medicare inpatient-only list, expanded site-neutral payment policies, and new AI-related laws and regulations, which may require significant resource allocation and operational adjustments.

Management Comments

• Our primary objective is to provide a comprehensive array of quality health care services in the most cost-effective manner possible.
• We strive to be the health care system of choice in the communities we serve by developing comprehensive networks locally and supporting these networks with enterprise expertise and economies of scale.
• We are committed to providing the communities we serve with high-quality, convenient and cost-effective health care while growing our business and creating long-term value for our stockholders.
• We believe our continued investment in the employment, recruitment and retention of physicians and other health care professionals will improve the quality of care at our facilities.
• We believe our centrally managed business processes and ability to leverage cost-saving practices across our extensive network will enable us to continue to manage costs effectively.
• We are investing in digital, data, and artificial intelligence capabilities to improve clinical quality, enhance the experience of our patients and colleagues, and drive operational efficiency at scale.
• Management expects a continuation of the challenges related to collection of patient due accounts.
• Management believes our reserves for self-insured retentions and insurance coverage are sufficient to cover insured claims arising out of the operation of our facilities, although some claims may exceed the scope or amount of the coverage limits of our insurance policies.
• Management believes HCA Healthcare, Inc., its subsidiaries and affiliates properly reported taxable income and paid taxes in accordance with applicable laws and agreements established with the IRS, state and foreign taxing authorities and final resolution of any disputes will not have a material, adverse effect on our results of operations or financial position.

Industry Context

StockSavvy.ai notes that HCA Healthcare's strong revenue and net income growth in 2025, coupled with increased patient volumes, indicates robust demand for healthcare services despite ongoing industry challenges. The strategic focus on expanding presence in existing markets, achieving industry-leading performance, recruiting and retaining healthcare professionals, leveraging economies of scale, and advancing digital and AI capabilities aligns with broader healthcare trends emphasizing efficiency, quality, and technological integration. The company's significant investment in AI and digital capabilities positions it to capitalize on the evolving landscape of healthcare delivery and administrative efficiency, a key differentiator in a competitive market. However, the anticipated decline in Medicaid SDP revenues and the expiration of enhanced premium tax credits highlight the persistent regulatory and economic pressures facing the sector, requiring continuous adaptation and 'resiliency efforts.'

Comparison to Industry Standards

• HCA's 7.1% revenue growth and 17.8% net income growth in 2025 are strong indicators of performance within the U.S. healthcare services sector, especially when compared to the S&P Health Care Index's 148.36 cumulative return over five years (ending Dec 31, 2025) versus HCA's 296.34. This suggests HCA is outperforming the broader healthcare market.
• The company's focus on digital and AI capabilities is a common theme among leading healthcare providers like Mayo Clinic and Cleveland Clinic, who are also investing heavily in these areas to improve patient outcomes and operational efficiency.
• The increasing cost of uncompensated care and the decline in outpatient surgical volumes could be areas where HCA faces similar or greater challenges compared to peers who might have different payer mixes or outpatient strategies.
• HCA operates in a highly competitive environment, with competition from physician-owned, tax-supported government, and not-for-profit entities that may have advantages in funding capital expenditures due to tax exemptions.

Management Changes

Corporate Governance

Legal Proceedings

• An affiliate was notified in December 2023 of an investigation by District Attorneys in four California counties regarding waste disposal practices and alleged violations of state environmental and other laws. The company is responding to requests for information and assessing allegations, not believing this matter will materially impact the company.

Related Party Transactions

• On February 6, 2026, the Company entered into an Exchange Agreement with Frisco, Inc., an entity controlled by the Company's founder, Dr. Thomas F. Frist, Jr., and certain of his affiliates (the Frist Entities). This involved the exchange of 36,629,188 shares of common stock for 36,557,141 new shares, constituting a tax-free reorganization to facilitate estate and charitable planning objectives of the Frist Entities.
• Frist-affiliated investors, through Hercules Holding II and Frisco Holding II, continue to hold approximately 31% of the outstanding common stock as of January 31, 2026, and retain the right to nominate certain members of the Board of Directors.
• Amended and Restated Stockholders Agreement, Registration Rights Agreement, and Indemnification Priority and Information Sharing Agreement were entered into with Hercules Holding II and Frisco Holding II, formalizing governance and registration rights for the Frist Group.

Stakeholder Impact

• **Shareholders:** Positive impact from increased net income, strong revenue growth, share repurchases, and increased dividends. The Frist Group maintains significant influence through board nomination rights.
• **Employees:** Continued investment in workforce development programs, competitive compensation and benefits, and efforts to improve retention and recruitment. However, labor shortages and potential union activity remain challenges.
• **Patients:** Commitment to high-quality, convenient, and cost-effective healthcare. Investments in clinical systems, digital capabilities, and AI aim to improve patient care. Increased uncompensated care costs indicate ongoing challenges for uninsured patients.
• **Customers (Payers):** Ongoing negotiations with managed care plans for favorable contracts. Price transparency initiatives and payer consolidation may impact contract terms.
• **Suppliers:** Potential impact from supply chain disruptions, shortages, and increased costs due to inflation and tariffs.
• **Creditors:** Significant indebtedness ($46.492 billion) and reliance on cash flows to service debt. Debt agreements contain covenants that limit flexibility.

Next Steps

• Continue recruiting and strategically collaborating with the physician community.
• Develop comprehensive service lines such as cardiology, neurology, oncology, orthopedics, and women's services.
• Provide access and convenience through developing various outpatient facilities (surgery centers, urgent care clinics, freestanding emergency care facilities, imaging centers, home health, and hospice services).
• Improve coordination of care and patient retention across markets.
• Continue to invest in initiatives such as care navigators, clinical data exchange, and centralized patient transfer operations.
• Focus on selectively developing and acquiring new hospitals, outpatient facilities, and other healthcare service providers.
• Advance clinical systems and digital capabilities.
• Transform care models with innovative care solutions.
• Expand workforce development programs.
• Enhance healthcare networks and partnerships.
• Fund planned capital expenditures of $5.0 billion to $5.5 billion in 2026.
• Complete projects under construction with an estimated additional cost of $7.1 billion over the next five years.
• Pay a quarterly dividend of $0.78 per share on March 31, 2026.
• Continue share repurchase programs, with $750 million remaining under the January 2025 authorization and a new $10 billion authorization in January 2026.
• Monitor and adapt to expected declines in Medicaid SDP revenues in 2026.
• Address anticipated adverse impacts from the expiration of enhanced premium tax credits and FBA provisions in 2026 through ongoing resiliency efforts.
• Monitor and comply with evolving AI-related laws and regulations.

Key Dates

Recommendation

HCA Healthcare's 2025 performance demonstrates robust financial health with substantial increases in net income and revenue, driven by strong patient volumes and effective revenue management. The company's strategic investments in digital and AI capabilities, coupled with disciplined capital allocation through share repurchases and increased dividends, signal a proactive approach to growth and shareholder value. While regulatory changes and labor costs present headwinds, the company's proven ability to navigate these challenges, its market leadership, and its commitment to operational excellence make it an attractive investment. The stock's historical outperformance against the S&P Health Care Index further supports a positive outlook.

Keywords

Healthcare, Hospital Management, SEC Filing, Financial Performance, Patient Volume, Revenue Growth, Net Income, Cash Flow, Debt Management, Share Repurchase, Dividends, Regulatory Compliance, Medicare, Medicaid, Managed Care, Cybersecurity, AI in Healthcare, Workforce Development, Risk Factors, Corporate Governance, HCA Healthcare